Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fevipiprant (NVP-QAW039) 是一种选择性、强效、可逆的竞争性 CRTh2 拮抗剂,KD 值为1.1 nM,IC50为0.44 nM,能够引发人体嗜酸性粒细胞的形状变化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 263 | 现货 | ||
5 mg | ¥ 597 | 现货 | ||
10 mg | ¥ 897 | 现货 | ||
25 mg | ¥ 1,830 | 现货 | ||
50 mg | ¥ 2,730 | 现货 | ||
100 mg | ¥ 4,130 | 现货 | ||
200 mg | ¥ 5,880 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 663 | 现货 |
产品描述 | Fevipiprant (NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist. |
靶点活性 | CRTH2:0.44 nM |
体外活性 | CRTh2-mediated shape change in eosinophils was used to profile QAW039 in whole blood and represents a physiologically relevant environment. The comparable IC50 values for QAW039 in the whole blood and isolated shape-change assays are consistent with its lower plasma-protein binding and its relatively slow dissociation kinetics that drive its increased potency .QAW039 is highly potent in whole-blood systems, with the IC50 value obtained consistent with the affinity values calculated from radioligand experiments. In a further disease-relevant cellular context, the potency of QAW039 in the isolated Th2 cell cytokine inhibition assay is consistent with its CRTh2 receptor affinity, and, as with eosinophil assay readouts, this represents an improved potency compared with QAV680.[ |
别名 | QAW039, NVP-QAW039, 非维匹仑 |
分子量 | 426.41 |
分子式 | C19H17F3N2O4S |
CAS No. | 872365-14-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fevipiprant 872365-14-5 Endocrinology/Hormones GPCR/G Protein Immunology/Inflammation GPR Prostaglandin Receptor QAW039 IL-4 inhibit Inhibitor bronchial asthma QAW-039 NVP-QAW-039 Th2 cells abdominal aortic aneurysm NVP-QAW039 orally active 非维匹仑 QAW 039 NVP-QAW 039 inhibitor